Investigating New Treatment Options for Triple Negative Breast Cancer

Posted on February 28, 2022

Lysyl Oxidase Research Spotlight Horizontal

Triple negative breast cancer (TNBC) accounts for 10-15% of all breast cancers. TNBC is a particularly dangerous type of cancer due to its rapid growth and spreading, but also because of limited treatment options currently available. TNBC lacks estrogen and progesterone receptors which means that hormone therapy is not a viable treatment option. And the absence of high levels of HER2 protein means that HER2 targeted drugs are not a treatment option either. Thus, the “triple negative” designation for this cancer, and the reason that treatment options are currently limited to mainly chemotherapies. Finding a better treatment option for TNBC is imperative.

Recent research has identified the tumor microenvironment as a target for selective delivery of chemotherapeutics to the tumor site. Specifically, the extracellular matrix (ECM) due to its promotion of tumor processes via remodelling. Delivering therapeutics to the tumor microenvironment represents a new strategy that could open the door for a promising generation of therapeutics.

Avanti’s Lipids and Targeting Lysyl Oxidase to treat TNBC

Lysyl oxidase 1 (LOX) is present in the ECM and represents a promising candidate for selective drug delivery to the tumor microenvironment. Previous research presented positive results related to the effectiveness of LOX targeted molecules, but associated safety profiles have been less than desirable. PLGA-nanoparticles with a LOX-blocking antibody have recently been investigated and proven quite effective at suppressing cancer cell growth. Until recently, lipid nanovesicles had not been studied as a delivery tool for LOX-targeted treatments.

In early 2021, that changed. Using several Avanti lipids, DSPC, cholesterol, DSPE-PEG(2000), and DSPE-PEG(2000)-succinyl, researchers prepared lipid vesicles engineered with anti-LOX and loaded with epirubicin (EPI). The lip-EPI-LOX vesicles were then used in vivo to treat mice with TNBC. And…. It worked! Really well. The LOX-engineered vesicles loaded with EPI were proven to be effective at treating TNBC, but not only were they effective, they were also safe. This treatment had a better safety profile than any other previously explored treatment options and was shown to have higher therapeutic activity, resulting in a higher rate of mice survival.

With higher therapeutic activity and lower toxicity, Lipo-EPI-LOX engineered lipid vesicles proved their potential as therapeutic agents for treatment of TNBC. This also proved the viability of targeting the ECM microenvironment of tumors for the safe and effective treatment of various cancers, including TNBC. We are excited and proud to see our lipid products being put to good use! If you are interested in purchasing lipids for your own therapeutic delivery research, visit our website! We offer a variety of lipids for formulating liposomes, lipid vesicles, and lipid nanoparticles. To learn more about the lipids used in this research just click on the name: DSPC, cholesterol, DSPE-PEG(2000), DSPE-PEG(2000)-succinyl. And to read the full research article, click HERE! We can’t wait to see what you will do!